LS CancerDiag looks back on the year marked by the achievement of major milestones. 2019 started off with obtaining the CE mark for DiagMMR® as in vitro diagnostic medical device (IVD MD), enabling commercialization in Europe. Shortly after, LS CancerDiag entered into distribution agreements in its home market covering virtually the whole of Finland.
Click below to read the full press release: